Deferred income represents a part of income received in 2015 and which will be used in 2016.

As at December 31, 2015, the non-profit organisation had a rental guarantee of KEUR 16 granted to the owner of the offices used by the non-profit organisation.

In 2015, Alzheimer Europe had an audited income of EUR 1,261,781.96 of which EUR 857,376.42 (67.95%) were for the organisation’s core activities (including the organisation’s Annual Conference) and EUR 404,405.54 (32.05%) were for the organisation’s annual conference, corporate affairs activities and other projects.

Funding of core activities (EUR 857,376.42)

In 2015, the core funding of Alzheimer Europe was composed as follows:

• EUR 422,880 (49.32%) from public funding,
• EUR 96,294.80 (11.23%) from foundations and other non-profit organisations,
• EUR 137,877.29 (16.08%) from member organisations,
• EUR 75,700 (8.83%) from corporate sources,
• EUR 123,764.76 (14.44%) from private individuals,
• EUR 859.57 (0.10%) from bank interest and similar.

Public funding

In 2015, Alzheimer Europe received EUR 422,880 as an operating grant from the European Commission

Foundations and organisations

The EUR 96,294.80 which Alzheimer Europe received in 2015 from foundations and other non-profit organisations can be broken down as follows:

• EUR 87,000 as direct support from Fondation Alzheimer, Luxembourg,
• EUR 5,294.80 from Fondation Roger de Spoelberch for the publication of the Alzheimer Europe Care Manual in Portuguese,
• EUR 4,000 from Fondation Médéric Alzheimer to support AE’s work on ethical challenges faced by professional carers.

Funding from member organisations

In 2015, the EUR 137,877.29 funding from member organisations can be broken down as follows:

• EUR 58,377.29 in membership fees and contributions
• EUR 79,500 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day).

Corporate support

In 2015, Alzheimer Europe received EUR 75,700 from corporate sources as core-funding which can be broken down as follows:

• EUR 35,000 from GlaxoSmithKline as support to the organisation’s core activities,
• EUR 10,000 from Hoffmann-LaRoche and Lilly to support the AE Conference in Ljubljana,
• EUR 5,700 from Newsweaver which provided an e-mail facility free of charge,
• EUR 5,000 from Nestlé, Piramal and SCA Global Hygiene to support the AE Conference in Ljubljana.

Private individuals

In 2015, AE received EUR 123,764.76 from individuals which can be broken down as follows:

• EUR 123,191.25 in conference registrations and
• EUR 573.51 in donations.

Bank interest and similar

In 2015, Alzheimer Europe had an income of EUR 859.57 from bank interest and similar income.

Funding of project activities (EUR 404,405.54)

In 2015, Alzheimer Europe received EUR 404,405.54 for its participation in various EU projects, a project on good incontinence care and its corporate affairs activities, of which

• EUR 217,385.51 (53.75%) came from corporate sponsors

• EUR 1,712.04 (0.42%) from private individuals,
• EUR 188,617.52 (46.64%) from public sources and
• EUR 8,704.32 (2.15%) from foundations and other non-profit organisations,
• EUR -12,013.85 (-2.97%) was project income deferred to 2016.

Corporate support

The corporate support received by Alzheimer Europe for its activities in 2015 (EUR 217,385.51) can be broken down as follows:

• Lilly contributed EUR 41,280 as a gold sponsor of AE’s corporate programme and as travel support,
• SCA Global Hygiene contributed EUR 32,350 as a bronze sponsor of AE’s corporate programme and towards the AE/SCA joint project on good incontinence care,
• Hoffmann-LaRoche contributed EUR 20,025 as a silver sponsor of AE’s corporate programme and as travel support,
• GE Healthcare and Janssen contributed EUR 20,000 each as silver sponsors of AE’s corporate programme,
• Nutricia contributed EUR 15,000 towards AE’s corporate programme,
• Lundbeck, Nestlé and Otsuka contributed EUR 12,500 each towards AE’s corporate programme,
• Merz and Piramal provided EUR 10,000 as bronze sponsors of AE’s corporate programme,
• Sandoz and Biogen provided EUR 5,000 as sponsors of AE’s corporate programme
• GSK provided EUR 1,230.51 in travel support and honoraria.

Private individuals

In 2015, Alzheimer Europe received EUR 1,712.04 in publication sales.

Public funding

In 2015, Alzheimer Europe received EUR 188,617.52 as public funding from its participation in various EU projects:

• EUR 52,650,11 for EPAD,
• EUR 26,411.36 for AETIONOMY,
• EUR 23,212.33 for AFE-INNOVNET,
• EUR 22,757.35 for PharmaCog,
• EUR 15,786.22 for PredictND,
• EUR 14,119.52 for PACE,
• EUR 9,628.72 for NILVAD,
• EUR 9,561.46 for Smart4MD,
• EUR 7,370.98 for a JPND health outcomes project and
• EUR 7,119.47 for EMIF.

Foundations and organisations

In 2015, Alzheimer Europe received a total of EUR 8,704.32 for other organisations and foundations, including EUR 6,846.27 from various organisations as travel grants and EUR 1,858.05 for secretarial costs provided to the Alzheimer Europe Foundation.

Deferred income

In 2015, Alzheimer Europe was able to contribute EUR 9,060.19 to its project activities which came from deferred income in 2014 and reported EUR 21,074.04 of its project income to 2016.

Overall funding

The following table lists all sources of income received in 2015.

In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.